We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Full-spectrum Medical Cannabis for Treatment of Spasticity in Patients With Severe Forms of Cerebral Palsy (HemPhar)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04634136
Recruitment Status : Recruiting
First Posted : November 18, 2020
Last Update Posted : April 4, 2022
Sponsor:
Collaborators:
PharmaHemp
University of Ljubljana, Faculty of Medicine
Information provided by (Responsible Party):
Damjan Osredkar, University Medical Centre Ljubljana

Brief Summary:
The proposed study is a double-blind, placebo-controlled, cross over study on 60 children aged 5 to 25 years with severe spasticity related to cerebral palsy (CP), level IV and V with full-spectrum medical cannabis product of CBD/THC ratio 10:1.

Condition or disease Intervention/treatment Phase
Children, Adult Spastic Cerebral Palsy Quality of Life Cannabis Physical Disability Diagnostic Test: Lab tests Diagnostic Test: ECG Diagnostic Test: Cannabinoid Levels Drug: Full-spectrum Medical Canabis Product (HemPhar) Drug: Placebo Diagnostic Test: Spasticity level according to modified Ashworth scale (Bohannon) Diagnostic Test: Gross Motor Function Measure Diagnostic Test: Borg rating of perceived exertion scale Diagnostic Test: Edmonton symptom assessment system Not Applicable

Detailed Description:

Test components:

A) Active: Full-spectrum medical cannabis with ratio of CBD:THC 10:1 (HemPhar)

B) Placebo (both of the same producer)

Study Steps

  1. Informed consent should be signed by parents/caregivers.
  2. Weight of the participant should be determined and an IV line inserted. The following lab tests should be performed: CBC and differential counts, blood electrolytes, magnesium, calcium, phosphorus, urea & creatinine, liver enzymes (AST, ALT, gGT)
  3. ECG performed and analyzed
  4. A trained physiotherapist will perform the following motor assessments: spasticity level according to modified Ashworth scale (Bohannon), function/activity assessment with the use of Gross Motor Function Measure scale (GMFM-88) and assessment of muscle power with dynamometer.
  5. Randomization of patients into one of the two arms of the study
  6. Active substance or placebo are introduced thereafter (as an oral oily solution for oral application) in a starting dose of 0.08 mg/kg body weight (BWt)/day divided in 2 doses (the dose is according to the THC content). The dose is gradually increased, every 3 days for 0.08 mg THC/ kg BWt/day, until the maximum dose of 1 mg THC/kg BWt/day is reached, or else until adverse effects are noted. It is expected that the average dose will be 0.33 mg/kg BWt per day.
  7. The parents/caregivers are given questionnaires/scales and also given oral instructions on how to fulfil them (Edmonton scale, Borg scale and Global Impression of Change - GIC) and the paper to take down notes on possible side/adverse effects while taking the preparation (either active substance or placebo).
  8. After 6 weeks of taking the substance or at the premature end of the study again the lab tests will be performed as well as the motor assessment by the physiotherapist (as above at inclusion).
  9. In patients, who have been receiving placebo for the first 6 weeks, the active substance is given for the next 6 weeks, as described above (under 6). The patients who have been receiving the active substance for the first 6 weeks will continue to do so for the next 6 weeks.
  10. Additional blood samples are taken at 6 weeks in both groups for analysis of levels of cannabidiol (CBD) as well as delta-9-tetrahydrocannbinol (THC) - around 4 ml of blood for determination of both levels at time(s) after ingestion: 0, 1, 2, 4, 8 and 24 hours.
  11. At the end of the study (after 12 weeks) again repeat:

    1. CBC and differential counts, blood electrolytes, magnesium, calcium, phosphorus, urea & creatinine, liver enzymes (AST, ALT, gGT)
    2. ECG
    3. Motor assessments by a physiotherapist (Ashworth/Bohannon, GMFM 88, dynamometer)
    4. Pharmacokinetics: 4 ml of blood for determination of phamacokinetics after ingestion of the last dose (as in point 10 above)
  12. Evaluation of the questionnaires

NOTE: if severe side/adverse effects are noted, the test compound should be stopped immediately. If mild/moderate side/adverse effects are noted, the test component should be gradually stopped: for 0,08 mg/kg BWt/day, every 3 days.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description:

Active substance: Full-spectrum medical cannabis product of CBD/THC ratio 10:1.

Arm 1: Active substance. The starting dose will be 0,08 mg THC per kilo body weight daily in 2 divided doses which will gradually be increased (escalating dose of 0,08 mg THC kg/d) until maximal dose of 1 mg/kg/d.

Arm 2: Placebo

Crossover: After 6 weeks Arm 2 will also receive the active substance and patients in both arms will continue receiving the active substance for the next 6 weeks.

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Placebo product will be of the same quantity and apperance (same packaging) as the active substance. All partricipants will be blinded to relevant patient data.
Primary Purpose: Treatment
Official Title: Full-spectrum Medical Canabis Product (HemPhar) With a CBD:THC Ratio of 10:1 for Treatment of Spasticity in Children and Young Adults With Severe Forms of Cerebral Palsy
Actual Study Start Date : October 15, 2020
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : June 2023


Arm Intervention/treatment
Active Comparator: Active Substance: Full-spectrum Medical Canabis Product (HemPhar)
For research purposes the investigators will use a preparation in the form of drops, containing full-spectrum medical cannabis extract (HemPhar) with THC:CBD ratio 1:10, and other cannabinoids as well, provided by Pharmahemp, GMP-certified medical cannabis producer.
Diagnostic Test: Lab tests
CBC and differential counts, blood electrolytes, magnesium, calcium, phosphorus, urea & creatinine, liver enzymes (AST, ALT, gGT)
Other Name: Basic hematology and biochemistry

Diagnostic Test: ECG
Electrocardiogram

Diagnostic Test: Cannabinoid Levels
Determination of levels of cannabidiol (CBD) and delta-9-tetrahydrocannbinol (THC) for determination of levels at following time(s) after ingestion: 0, 1, 2, 4, 8 and 24 hours.
Other Name: Pharmacokinetics of cannabinoids

Drug: Full-spectrum Medical Canabis Product (HemPhar)
Active substance
Other Name: Active substance

Diagnostic Test: Spasticity level according to modified Ashworth scale (Bohannon)

A trained physiotherapist will assess spasticity level according to modified Ashworth scale (Bohannon), which is 6-level scale for assessment of spasticity.

Modified Ashworth/Bohannon Scoring Scale (Bohannon and Smith, 1987):

0 No increase in muscle tone

  1. Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension 1+ Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the range of movement (ROM )
  2. More marked increase in muscle tone through most of the ROM, but affected part(s) easily moved
  3. Considerable increase in muscle tone, passive movement difficult
  4. Affected part(s) rigid in flexion or extension

Best score is 0 (no spasticity), worst score is 4 (severe spasticity).


Diagnostic Test: Gross Motor Function Measure

A trained physiotherapist will assess Gross Motor Function Measure (GMFM-88) which is commonly used in the evaluation of gross motor function in children with cerebral palsy

The Gross Motor Function Measure-88 (GMFM-88) is a standardized observational instrument developed to measure change in gross motor function over time. The test consists of 88 items categorized in five dimensions (Dimension A: lying and rolling, Dimension B: sitting, Dimension C: crawling and kneeling, Dimension D: standing and Dimension E: walking, running and jumping). The test was conducted as described in the GMFM-88 manual . A percentage score as compared to maximum is calculated for each dimension and for the total score of the five dimensions.

Reference curves exist for GMFM-88 for each age group.

Floor score is 4 (minimum score / worst), ceiling score (maximum score / best) is 75.


Diagnostic Test: Borg rating of perceived exertion scale
Borg rating of perceived exertion scale

Diagnostic Test: Edmonton symptom assessment system
Edmonton symptom assessment system and general impression scale (1 - very much improved; 7 - very much worse).

Placebo Comparator: Placebo
For research purposes the investigators will use a placebo in the form of drops, containing oil only, provided by Pharmahemp, GMP-certified medical cannabis producer.
Diagnostic Test: Lab tests
CBC and differential counts, blood electrolytes, magnesium, calcium, phosphorus, urea & creatinine, liver enzymes (AST, ALT, gGT)
Other Name: Basic hematology and biochemistry

Diagnostic Test: ECG
Electrocardiogram

Drug: Placebo
Placebo

Diagnostic Test: Spasticity level according to modified Ashworth scale (Bohannon)

A trained physiotherapist will assess spasticity level according to modified Ashworth scale (Bohannon), which is 6-level scale for assessment of spasticity.

Modified Ashworth/Bohannon Scoring Scale (Bohannon and Smith, 1987):

0 No increase in muscle tone

  1. Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension 1+ Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the range of movement (ROM )
  2. More marked increase in muscle tone through most of the ROM, but affected part(s) easily moved
  3. Considerable increase in muscle tone, passive movement difficult
  4. Affected part(s) rigid in flexion or extension

Best score is 0 (no spasticity), worst score is 4 (severe spasticity).


Diagnostic Test: Gross Motor Function Measure

A trained physiotherapist will assess Gross Motor Function Measure (GMFM-88) which is commonly used in the evaluation of gross motor function in children with cerebral palsy

The Gross Motor Function Measure-88 (GMFM-88) is a standardized observational instrument developed to measure change in gross motor function over time. The test consists of 88 items categorized in five dimensions (Dimension A: lying and rolling, Dimension B: sitting, Dimension C: crawling and kneeling, Dimension D: standing and Dimension E: walking, running and jumping). The test was conducted as described in the GMFM-88 manual . A percentage score as compared to maximum is calculated for each dimension and for the total score of the five dimensions.

Reference curves exist for GMFM-88 for each age group.

Floor score is 4 (minimum score / worst), ceiling score (maximum score / best) is 75.


Diagnostic Test: Borg rating of perceived exertion scale
Borg rating of perceived exertion scale

Diagnostic Test: Edmonton symptom assessment system
Edmonton symptom assessment system and general impression scale (1 - very much improved; 7 - very much worse).




Primary Outcome Measures :
  1. Effect on spasticity (6w; FSMC vs placebo) [ Time Frame: 6 weeks ]

    A trained physiotherapist will assess spasticity level according to modified Ashworth scale (Bohannon), which is 6-level scale for assessment of spasticity.

    Modified Ashworth/Bohannon Scoring Scale (Bohannon and Smith, 1987):

    0 No increase in muscle tone

    1. Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension 1+ Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the range of movement (ROM )
    2. More marked increase in muscle tone through most of the ROM, but affected part(s) easily moved
    3. Considerable increase in muscle tone, passive movement difficult
    4. Affected part(s) rigid in flexion or extension

    Best score is 0 (no spasticity), worst score is 4 (severe spasticity).


  2. Effect on Gross Motor Function Measure (6w; FSMC vs placebo) [ Time Frame: 6 weeks ]

    A trained physiotherapist will assess Gross Motor Function Measure (GMFM-88) which is commonly used in the evaluation of gross motor function in children with cerebral palsy

    The Gross Motor Function Measure-88 (GMFM-88) is a standardized observational instrument developed to measure change in gross motor function over time. The test consists of 88 items categorized in five dimensions (Dimension A: lying and rolling, Dimension B: sitting, Dimension C: crawling and kneeling, Dimension D: standing and Dimension E: walking, running and jumping). The test was conducted as described in the GMFM-88 manual . A percentage score as compared to maximum is calculated for each dimension and for the total score of the five dimensions.

    Reference curves exist for GMFM-88 for each age group.

    Floor score is 4 (minimum score / worst), ceiling score (maximum score / best) is 75.


  3. Effect on spasticity (12w; 12w-FSMC vs 6w-FSMC) [ Time Frame: 12 weeks ]

    A trained physiotherapist will assess spasticity level according to modified Ashworth scale (Bohannon), which is 6-level scale for assessment of spasticity

    Modified Ashworth/Bohannon Scoring Scale (Bohannon and Smith, 1987):

    0 No increase in muscle tone

    1. Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension 1+ Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the range of movement (ROM )
    2. More marked increase in muscle tone through most of the ROM, but affected part(s) easily moved
    3. Considerable increase in muscle tone, passive movement difficult
    4. Affected part(s) rigid in flexion or extension

    Best score is 0 (no spasticity), worst score is 4 (severe spasticity).


  4. Effect on Gross Motor Function Measure (12w; 12w-FSMC vs 6w-FSMC) [ Time Frame: 12 weeks ]

    A trained physiotherapist will assess Gross Motor Function Measure (GMFM-88) which is commonly used in the evaluation of gross motor function in children with cerebral palsy.

    The Gross Motor Function Measure-88 (GMFM-88) is a standardized observational instrument developed to measure change in gross motor function over time. The test consists of 88 items categorized in five dimensions (Dimension A: lying and rolling, Dimension B: sitting, Dimension C: crawling and kneeling, Dimension D: standing and Dimension E: walking, running and jumping). The test was conducted as described in the GMFM-88 manual . A percentage score as compared to maximum is calculated for each dimension and for the total score of the five dimensions.

    Reference curves exist for GMFM-88 for each age group.

    Floor score is 4 (minimum score / worst), ceiling score (maximum score / best) is 75.


  5. Safety and tolerability of FSMC [ Time Frame: 12 weeks ]
    Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   5 Years to 25 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • With confirmed diagnosis of cerebral palsy (CP) and classified according to the Gross Motor Function Classification System (GMFCS) as level IV or V
  • With spastic unilateral or spastic bilateral type of CP
  • Those children/young adults whose parents/caregivers were informed about the aims of the study and have signed the Informed consent form

Exclusion criteria:

  • Other proven diseases/conditions with the prevalence of spastic type of muscle tone (e.g. neurodegenerative, metabolic, etc.), and children with liver disease
  • Other forms of CP (dyskinetic, ataxic)
  • History of psychiatric illness/condition in the family

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04634136


Contacts
Layout table for location contacts
Contact: Milica Stefanović, MD +386(01)522 ext 9215 milica.stefanovic@kclj.si
Contact: David Neubauer, MD,PhD +386(01)522 ext 9231 david.neubauer@mf.uni-lj.si

Locations
Layout table for location information
Slovenia
PharmaHemp Active, not recruiting
Ljubljana, Slovenia, 1000
University Medical Centre Ljubljana Recruiting
Ljubljana, Slovenia
Contact: Damjan Osredkar, MD, PhD       damjan.osredkar@kclj.si   
Sub-Investigator: Milica Stefanovič, MD         
Sub-Investigator: David Neubauer, MD, PhD         
Sub-Investigator: Alenka Piskar         
Sub-Investigator: Zvonka Rener Primec, MD, PhD         
Sub-Investigator: Anja Troha Gergeli, MD         
Sub-Investigator: Tita Butenko, MD         
Principal Investigator: Damjan Osredkar, MD, PhD         
Sponsors and Collaborators
University Medical Centre Ljubljana
PharmaHemp
University of Ljubljana, Faculty of Medicine
Investigators
Layout table for investigator information
Principal Investigator: Damjan Osredkar, MD, PhD UMC Ljubljana
Layout table for additonal information
Responsible Party: Damjan Osredkar, Associate Professor of Pediatrics, University Medical Centre Ljubljana
ClinicalTrials.gov Identifier: NCT04634136    
Other Study ID Numbers: 0120-162/2017/8
First Posted: November 18, 2020    Key Record Dates
Last Update Posted: April 4, 2022
Last Verified: March 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Damjan Osredkar, University Medical Centre Ljubljana:
cerebral palsy
severe spasticity
child
cannabis treatment
quality of life
young adult
Additional relevant MeSH terms:
Layout table for MeSH terms
Muscle Spasticity
Paralysis
Cerebral Palsy
Marijuana Abuse
Neurologic Manifestations
Nervous System Diseases
Brain Damage, Chronic
Brain Diseases
Central Nervous System Diseases
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Muscular Diseases
Musculoskeletal Diseases
Muscle Hypertonia
Neuromuscular Manifestations